Together, our preclinical and patient data demonstrate that activation of the AR-FUT4 axis contributes to the disparately worse clinical outcomes observed in male patients by disrupting cellular adhesion and driving tumor cell migration and invasion. The gene discussed is FUT4; the disease is neoplasm.